Towards a more personalized approach in the treatment of esophageal cancer focusing on predictive factors in response to chemoradiation

Wang, D. 2017 [Groningen]: University of Groningen. 160 p.

Research output: ScientificDoctoral Thesis

Copy link to clipboard


  • Title and contents

    Final publisher's version, 127 KB, PDF-document

  • Chapter 1

    Final publisher's version, 385 KB, PDF-document

  • Chapter 2

    Final publisher's version, 1 MB, PDF-document

  • Chapter 3

    Final publisher's version, 5 MB, PDF-document

    Embargo ends: 09/10/2018

  • Chapter 4

    Final publisher's version, 7 MB, PDF-document

    Embargo ends: 09/10/2018

  • Chapter 5

    Final publisher's version, 5 MB, PDF-document

    Embargo ends: 09/10/2018

  • Chapter 6

    Final publisher's version, 249 KB, PDF-document

  • Chapter 7

    Final publisher's version, 942 KB, PDF-document

  • Chapter 8

    Final publisher's version, 116 KB, PDF-document

  • Chapter 9

    Final publisher's version, 128 KB, PDF-document

  • Acknowledgement

    Final publisher's version, 114 KB, PDF-document

  • Curriculum Vitae

    Final publisher's version, 90 KB, PDF-document

  • List of publications

    Final publisher's version, 85 KB, PDF-document

  • Complete thesis

    Final publisher's version, 20 MB, PDF-document

    Embargo ends: 09/10/2018

  • Propositions

    Final publisher's version, 60 KB, PDF-document

The prognosis of esophageal cancer is poor as most patients present with locally advanced or metastatic disease. The treatment of choice in patients with locally advanced disease (T2-4a/N1-3/M0) is radical surgery with neoadjuvant chemoradiation. Nevertheless, even after neoadjuvant chemoradiation, recurrences occur frequently and complete responses are still relatively low. The response rate of neoadjuvant treatment (41.4 Gy with concurrent carboplatin/paclitaxel) varies between 22%-35%. Another problem is the high rate of recurrences (up to 50%), even after a pathologic complete response (pCR). To gain more insight in the cause of the relatively low response rate and recurrences after pCR, we need to obtain a better understanding of the nature of these tumors and determine better predictive factors. A population of cells the so-called cancer stem-like cells (CSCs) is known to be highly resistant to chemoradiation and therefore targeting these cells might contribute to a better response. With good predictive factors a better choice can be made regarding the potential effect of neoadjuvant treatment as well as surgical resection leading to more personalized therapy. The goal of this research is to identify new predictive factors for the response to neoadjuvant chemoradiation in esophageal cancer and to find therapies to target the CSC population potentially leading to a better response.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date9-Oct-2017
Place of Publication[Groningen]
Print ISBNs978-94-034-0156-0
Electronic ISBNs978-94-034-0155-3
StatePublished - 2017

View graph of relations

Download statistics

No data available

ID: 48649499